PBGENE-DMD Gene Editing Therapy is an investigational, first-in-class treatment developed by Precision BioSciences for Duchenne muscular dystrophy (DMD).
Unlike traditional therapies, PBGENE-DMD uses a gene excision strategy powered by ARCUS gene editing technology. It is delivered via a single adeno-associated virus (AAV) vector that encodes two ARCUS nucleases designed to permanently edit the dystrophin gene.
This approach aims to:
- Remove faulty sections of DNA within the dystrophin gene
- Enable the body to produce a near full-length, functional dystrophin protein
- Provide long-term and potentially durable muscle improvement
Preclinical data show that PBGENE-DMD can restore dystrophin expression across multiple muscle types, including skeletal muscle, diaphragm, and cardiac tissue, while also editing muscle satellite stem cells, which are critical for sustained benefit .
Table of Contents
Why Is PBGENE-DMD Gene Editing Therapy Important?
PBGENE-DMD represents a major shift in Duchenne treatment strategy, offering several potential advantages over existing therapies:
Permanent Gene Editing
Most current treatments, such as exon skipping, require repeated dosing and provide temporary effects. PBGENE-DMD aims to permanently modify DNA, potentially offering a one-time treatment approach.
Near Full-Length Dystrophin Production
Unlike microdystrophin therapies that produce shortened proteins, PBGENE-DMD is designed to restore a more complete and functional dystrophin protein, which may improve clinical outcomes.
Targeting Muscle Stem Cells
By editing satellite cells, PBGENE-DMD may support ongoing muscle regeneration and long-term durability, a key limitation of other therapies.
Multi-Tissue Impact
Preclinical studies demonstrate effects in:
- Skeletal muscle
- Cardiac muscle
- Diaphragm
This is especially important given the role of heart and respiratory failure in DMD progression.
Regulatory Recognition
PBGENE-DMD has received important designations from the FDA, including:
- Fast Track designation
- Orphan Drug designation
- Rare Pediatric Disease designation
Who Can Receive PBGENE-DMD Gene Editing Therapy? (Eligibility FAQs)
The following criteria are based on clinical trial eligibility requirements .
✅ Eligible Patients
Which exon deletions are eligible for PBGENE-DMD gene editing therapy?
Patients must have a confirmed DMD mutation fully contained within exons 45–55.
What physical abilities are required?
Ages 2 to <4 years:
• Ability to walk at least 10 meters independently
• Ability to rise from the floor (Gowers’ maneuver allowed)
Ages 4 to 7 years:
• Ability to walk at least 100 meters independently
• NSAA score between 16 and 29
Learn More: NSAA
Are vaccinations required?
Yes. Patients must be up to date with routine childhood immunizations.
Is consent required?
Yes. Parents or legal guardians must provide written informed consent, and children must provide assent where applicable.
Is long-term follow-up required?
Yes. Patients must agree to participate in a long-term follow-up (LTFU) study.
Who Is NOT Eligible for PBGENE-DMD? (Exclusion FAQs)
❌ Ineligible Patients
Can patients with prior gene therapy participate?
No. Any history of:
• Gene therapy
• Gene editing
• Cell-based therapy
→ results in exclusion.
What about exon skipping or dystrophin therapies?
Patients are excluded if they:
• Used such therapies within the last 6 months
• Are unwilling to stop them for at least 5 years after treatment
Are patients in other clinical trials eligible?
No, unless the trial is observational (non-interventional).
Are AAV antibody-positive patients eligible?
No. A positive AAV9 antibody test excludes participation.
Are all DMD mutations eligible?
Participants with pathogenic mutations in exons 1-44 and/or exons 56-79.
What cardiac conditions exclude patients?
Patients with:
• Left ventricular ejection fraction (LVEF) < % 50
• Evidence of cardiomyopathy are excluded.
Can patients with immunosuppression contraindications participate?
No. Since gene therapy requires immunosuppression, such patients are not eligible.
PBGENE-DMD Gene Editing Therapy: FAQs from Families
Can a child treated with Elevidys also receive PBGENE-DMD gene editing therapy?
No. Patients who have previously received gene therapy like Elevidys are not eligible for PBGENE-DMD because prior gene therapy exposure is an exclusion criterion. In addition, immune responses to AAV vectors may reduce safety and effectiveness, and repeat gene-based treatments are generally avoided in current clinical protocols.
Can my son with an exon 43 deletion in the DMD gene receive PBGENE-DMD gene editing therapy?
No. PBGENE-DMD is designed for mutations fully contained within exons 45–55. An exon 43 deletion falls outside this target range, so it does not meet the current eligibility criteria.
Can my son with a deletion of exons 48–55 receive PBGENE-DMD gene editing therapy?
Technically, he may be eligible because this deletion falls within the target exon 45–55 range. However, deletions of exons 48–55 are more commonly associated with Becker muscular dystrophy, which typically has a milder course. Therefore, it would be prudent to wait for Precision BioSciences to expand research in this subgroup and publish clinical outcomes. Given the slower progression of BMD, careful monitoring and patience are advisable.
Is PBGENE-DMD a treatment option for boys with exon 45 deletion DMD?
Yes. PBGENE-DMD is designed for patients with mutations fully contained within exons 45–55, and an exon 45 deletion falls within this target range. Therefore, boys with this mutation may be eligible, provided they also meet other clinical criteria such as age, functional status, and overall health requirements.
Learn More: ARCUS Genome Editing
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic
Precision BioSciences announced new preclinical data from its PBGENE-DMD program in an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting.
PBGENE-DMD in early-juvenile mice achieved up to 3x higher dystrophin protein restoration in skeletal muscle, and up to 12x higher dystrophin protein restoration in respiratory muscle, compared with late-juvenile mice at equivalent dose levels.
Strong efficacy which exceeded the expected dystrophin protein restoration therapeutic threshold of % 5 was observed in respiratory muscle tissues, with mice achieving up to % 12 dystrophin restoration in the diaphragm and up to % 30 in the intercostals, muscles whose function is critical to preventing respiratory failure in patients with DMD.
A toxicology study in a humanized DMD mouse model showed that PBGENE-DMD treatment led to greater than 45% redtruction in serum creatine kinase across multiple dose levels, alongside improvements in muscle pathology relative to vehicle-treated controls, supporting the safety profile of the program.
PBGENE-DMD drove high levels of dystrophin-positive fibers in early-juvenile mice, with levels 2–3x higher in skeletal and respiratory muscle tissues than in late-juvenile mice after three months, reaching up to 70 percent dystrophin-positive fibers.
Similar therapeutic efficacy was achieved in cardiac muscle in both early- and late-juvenile mice.
Beyond safety, PBGENE-DMD has demonstrated sustained efficacy over time through dystrophin protein restoration and dystrophin-positive myofibers, translating into durable muscle function.
Treated mice maintained up to ’92 percent’ of the maximum force output of non-diseased animals, while untreated, diseased mice showed progressively declining force output.
Final Thoughts
PBGENE-DMD gene editing therapy signals a shift toward durable genetic correction in Duchenne muscular dystrophy. By targeting the root cause, it may enable near full-length dystrophin restoration. Its one-time approach could outperform repeat-dose therapies. Still, strict eligibility criteria limit access. Safety, durability, and real-world outcomes remain under study. Ongoing trials will define its long-term clinical impact.
Follow This Page >>> All Clinical Trials for Duchenne
My child is 16 years old with Exon deletion 45-47 and I want to participate please help me to get this treatment my child is able to walk and do all his work by his own.from where I can get this treatment please let me know as early as possible
We are not sure but can try as a group
Oğlum 48-51 arası 6 yaşında şuan için hareketli belirtisi olmayan bir çocuk ilerki zamanlarda yada hiç belirti olmadan bu tedavi uygulanabilirmi
Hello my son is 13 year with 49-55deletion non embulatery .can he us eligible for this threpy
Sir my son exon skipping from 45 to 54
My son 43 number exon missing his age is 6 year hi is full working